

Lingxiang Liu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1767714/lingxiang-liu-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30 papers	1,474 citations	17 h-index	31 g-index
31 ext. papers	1,921 ext. citations	7.9 avg, IF	4.35 L-index

#	Paper	IF	Citations
30	Exosomal circLPA1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3-eIF3h interaction.. <i>Molecular Cancer</i> , 2022 , 21, 49	42.1	6
29	Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. <i>Lung Cancer</i> , 2021 , 162, 86-89	5.9	0
28	Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2021 , 19, 330	3.4	0
27	Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. <i>Molecular Cancer</i> , 2021 , 20, 13	42.1	64
26	The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics. <i>Annals of Palliative Medicine</i> , 2020 , 9, 967-978	1.7	11
25	Genetic variants in circTUBB interacting with smoking can enhance colorectal cancer risk. <i>Archives of Toxicology</i> , 2020 , 94, 325-333	5.8	2
24	NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy. <i>Oncologist</i> , 2020 , 25, e955-e963	5.7	22
23	Sex disparities in cancer. <i>Cancer Letters</i> , 2019 , 466, 35-38	9.9	16
22	Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer. <i>Cancer Medicine</i> , 2019 , 8, 3428-3436	4.8	4
21	Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. <i>Nature Metabolism</i> , 2019 , 1, 431-444	14.6	76
20	Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data. <i>Translational Oncology</i> , 2018 , 11, 1119-1127	4.9	12
19	Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. <i>Cancer Cell</i> , 2016 , 29, 711-722	24.3	151
18	Effects of high-intensity focused ultrasound for treatment of abdominal lymph node metastasis from gastric cancer. <i>Journal of Ultrasound in Medicine</i> , 2015 , 34, 435-40	2.9	5
17	TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. <i>Cancer Research</i> , 2015 , 75, 3728-37	10.1	354
16	The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data. <i>BioMed Research International</i> , 2015 , 2015, 763080	3	12
15	Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. <i>International Journal of Clinical Oncology</i> , 2014 , 19, 303-11	4.2	19
14	A systematic analysis of predicted MiR-31-targets identifies a diagnostic and prognostic signature for lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2014 , 68, 419-27	7.5	17

13	MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 442-8	5.9	15
12	A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population. <i>PLoS ONE</i> , 2013 , 8, e79135	3.7	20
11	Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. <i>PLoS ONE</i> , 2013 , 8, e63654	3.7	55
10	Genetic variation in a microRNA-502 binding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. <i>PLoS ONE</i> , 2013 , 8, e77024	3.7	24
9	MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. <i>FEBS Journal</i> , 2012 , 279, 3800-12	5.7	66
8	Sequential transcatheter arterial chemoembolization, three-dimensional conformal radiotherapy, and high-intensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients. <i>Journal of Biomedical Research</i> , 2012 , 26, 260-7	1.5	12
7	The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1057-62	4.9	20
6	Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. <i>Clinical Lung Cancer</i> , 2012 , 13, 44-51	4.9	34
5	MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2012 , 13, 330-40	4.6	116
4	Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. <i>Clinical Lung Cancer</i> , 2011 , 12, 14-7	4.9	30
3	MIR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 557-66	4.9	197
2	The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1922-32	8.9	89
1	CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. <i>Cell Cycle</i> , 2009 , 8, 2578-85	4.7	25